[ADVERT]
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 2.48% 82.60 81.40 82.60 82.60 80.40 80.40 163,853 16:35:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 33.7 383

Ekf Diagnostics Share Discussion Threads

Showing 3851 to 3874 of 3950 messages
Chat Pages: 158  157  156  155  154  153  152  151  150  149  148  147  Older
DateSubjectAuthorDiscuss
28/9/2021
09:39
I like the deal and note this: "including a testing offering that our industry partners have been looking for us to provide". Amazon?? But unless I am missing something, the 2 year lock in is a bit of window dressing. From the RNS: (1) after the date that is sixty (60) days following completion, the vendors may sell in aggregate up to twenty percent (20%) of the total number of Consideration Shares held by them collectively; (2) after the date that is six (6) months following completion, the vendors may sell up to a total of fifty percent (50%) of the total number of Consideration Shares (including any such shares sold under (1) above); and (3) after the first anniversary of the completion date, the vendors may sell all of the Consideration Shares held by them So what is being locked in for 2 years - excepting that ADL BOD need to go to EKF and ask for permission?
melody9999
28/9/2021
09:27
Singer Capital Markets has published a new research note on EKF Diagnostics Holdings plc. Acquisition of diagnostic service lab EKF has made its first acquisitive move under the revised strategy, acquiring ADL Health, a USbased CLIA-accredited diagnostic service laboratory. It is paying $10m up front in EKF shares, with a performance-based three year earnout. In the 6m to Jun-21, ADL generated $6.3m revenues and $2.6m EBITDA giving an attractive initial purchase multiple of 1.3x Revenues and ~2.0x EBITDA. The acquisition provides EKF with a platform to complement and broaden the group’s existing diagnostic capabilities and should enhance its overall growth prospects. hTTps://www.research-tree.com/companies/uk/medical-equipment-services/ekf-diagnostics-holdings-plc/research/singer-capital-markets/acquisition-of-diagnostic-service-lab/24d32553-0e66-4cd4-8c5c-f87a87371b8a/827dc667-68bf-4394-acc6-93cefcbcb019
wan
28/9/2021
08:28
I think taking the all share dealshows a lot of faith by the owners of the acquired company. THere may be tax breaks in it, but then again EKF maynot have been the only suitor.
faz
28/9/2021
08:00
For ease of access, I have added EKF's 2021 – 2024 Growth Strategy to the header.
wan
28/9/2021
07:51
EKF takes a big step closer to the patient! The high confidence exhibited by the acquired owners in EKF is notable. For an initial dilution of 2% for an earnings enhancing, cash generative acquisition, in a combination that dovetails very well with the growth strategy, especially in terms of expanded diagnostics, looks insightful and considered. From EKF's Growth Strategy - CLIA lab for diagnostic tests – Further area of partnership with global private sector partner – Potential to link to Trellus, Renalytix and Verici – Move into $4bn US diagnostic testing market which has forecast CAGR of 13% from 2021 to 2027 The dawn of a new era is upon us!
wan
28/9/2021
07:16
Good news - an earnings-enhancing $10m acquisition of a Texas-based lab. The ambitions of the acquiree are clear to see - the deferred consideration is capped at a whopping $60m based on huge and immediate growth, and the vendors are taking an all-share purchase consideration and are locked in for two years: https://uk.advfn.com/stock-market/london/ekf-diagnostics-EKF/share-news/EKF-Diagnostics-Holdings-PLC-Acquisition-of-Advanc/86147872
rivaldo
27/9/2021
15:02
79 if you ask me but yes and it is a minor difference.
tongosti
27/9/2021
14:55
Looks like 80p is now sustainable benchmark. Been above that mark since the jump on the 10th. I’ll take it.
jsredbird
27/9/2021
11:03
B/o still in play by the skin of its teeth chaps. Amazed at such low volume consolidation
tongosti
24/9/2021
08:30
Christopher Mills mentions EKF at 30:24 in the latest Interview with PIWORLD Watch the video here: Https://www.piworld.co.uk/education-videos/piworld-interview-with-christopher-mills-spotting-value-doing-something-about-it/ Or listen to the podcast here: Https://piworld.podbean.com/e/piworld-interview-with-christopher-mills-spotting-value-doing-something-about-it/
tomps2
22/9/2021
15:16
Tic toc tic toc mg
tongosti
21/9/2021
13:55
But it hasn't tongosti, the price has been volatile over that period. Did you manage to buy the dips?
crazycoops
21/9/2021
09:43
How come the price has done FÃ from 9 Nov 2020 then? Lol
tongosti
21/9/2021
07:56
The Delta wave and the Biden announcement has materially changed demand in the US. The following story adds further context to the above stories - Thermo Fisher COVID-19 testing forecast tops estimates, crushes 2022 guidance Published Sept. 20, 2021 By Nick Paul Taylor Contributor Dive Brief: Thermo Fisher Scientific has forecast COVID-19 testing revenues will come in 100% above the expectations of Evercore ISI analysts in 2022 as testing demand returns amid the delta variant surge Dive Insight: Thermo Fisher has previously predicted coronavirus testing response revenues will total $4.9 billion this year. In discussing the longer-term prospects at a Friday investor day, Thermo Fisher management said most of the COVID-19 testing revenue will ramp down as the pandemic comes to an end. Exactly how quickly sales ramp down will influence Thermo Fisher's revenues in 2022 and potential beyond. With multiple COVID-19 testing companies reporting cratering demand, at least before the recent delta wave in the U.S., analysts had low expectations for Thermo Fisher’s activities in the space. The actual forecast came in 105% above the estimate of analysts at Evercore ISI. The analysts wrote that Thermo Fisher's financial targets set the company "apart from peers." In the brief history of the COVID-19 testing market, several companies have been forced to walk back from earlier predictions in response to rapid declines in demand. However, Thermo Fisher CEO Marc Casper expressed confidence that the $750 million target is an achievable baseline objective. "We actually de-risked the assumptions within the numbers for this year, as well as for next year, where we picked a number that I think you have a very high degree of confidence that you're going to be able to deliver. But there's obviously a range of outcomes above that as well ... depending on how long the pandemic plays out and what the back-to-life applications are," Casper said. Full story - hTTps://www.medtechdive.com/news/thermo-fisher-investor-day-covid-testing/606825/ Add into the mix EKF's improving trading in the core business, not to mention EKF's investments in the existing core business to maximise the value of their distribution network and drive aggressive organic growth, means we are well placed to benefit from the increased focus and increasing demand on healthcare.
wan
20/9/2021
17:28
As I reported previously, we know from the recent Biden announcement and the subsequent imminent regulation that all firms with 100 employees or more will need to require that workers get vaccinated or undergo weekly testing. And that that could nearly double the volume of tests currently being processed, which has already 'significantly' increased demand for COVID-19 testing, including PCR testing. The following article adds further context - Prognosis Biden’s Vaccine Mandate Risks Overwhelming U.S. Testing Capacity By Emma Court 14 September 2021 Some 81 million Americans worked at firms with 100 or more employees as of early 2020, according to the U.S. Bureau of Labor Statistics. If about a quarter of that population remains unvaccinated, as many as 20 million individuals could require weekly screenings -- a rate of nearly 3 million tests per day. By contrast, about 10 million Americans were tested each week, on average, over the last month, data compiled by Bloomberg show. The Biden administration announced last week that the Department of Labor’s Occupational Safety and Health Administration would soon implement the emergency regulation, and those who do not comply could face fines of up to $14,000 for each violation. It also earmarked $2 billion for 280 million rapid tests for use in community sites like schools and food banks, and said the Defense Production Act will be used to build out testing manufacturing capabilities. “Right now, there’s simply not enough tests available to do the testing that’s being called for,” said Jennifer Nuzzo, lead epidemiologist for the Johns Hopkins University’s Covid-19 testing insights initiative. Harvard’s Mina estimates that as much as two or three times as much testing may be going on than officially accounted for. And while the 280 million rapid tests being purchased by the government sounds like a large figure, it translates to “less than one test per person, per year” across the U.S. population, he said. Ramping up the manufacturing of rapid testing products would help satiate growing demand, Mina said. Part of what the administration’s purchase of those tests could do is signal to manufacturers that there is a longer-term market for virus screenings. Depending on those details, and because of tight rapid testing supply, employers may end up turning to laboratories to process polymerase chain reaction (PCR) tests. The American Clinical Laboratory Association, an industry group, said in a statement Thursday that its members “stand ready to support these efforts and ensure the widespread availability of these critical tests.” Adam Schechter, the chief executive officer of Laboratory Corp of America Holdings, said that the company has had employers reach out asking about services for testing and vaccination assistance since the Biden announcement last week. Schechter emphasized the role of rapid testing in large-scale screening like the kind in the new Biden administration plan. He said that laboratories have capacity to conduct PCR testing for those who test positive on a rapid test, who have symptoms or have been exposed to Covid. Full story, worth reading - hTTps://www.bloomberg.com/news/articles/2021-09-14/biden-s-workplace-vaccine-mandate-could-strain-testing-capacity I also note the recent US Department of Defense announcement regarding the procurement of rapid antigen testing (which can ultimately result in the requirement of a PCR test, or simply PCR testing anyway) - US Department of Defense Awards $647M to Procure Rapid Antigen Tests Sep 20, 2021 | staff reporter All of the contracts run from October 2021 through September 2022. hTTps://www.360dx.com/covid-19/us-department-defense-awards-647m-procure-rapid-antigen-tests#.YUijGbhKiF4 I am aware of some antigen tests that utilise a buffered saline solution with an antimicrobial agent, but nontoxic at the levels contained in the solution, so these tests can also be used for at home testing, which provides further food for thought.
wan
20/9/2021
11:42
What's more interesting is the lack of follow up. Fundamental analysis is worth nada unless the share price plays ball. Still in but getting ready to cut it loose if most recent b/o is invalidated as I described last week.
tongosti
20/9/2021
07:56
Interesting updates from both Myhealthchecked and SourceBio today confirming the significant increase in testing to date and that certain Covid-19 testing requirements will still be required for the foreseeable, generating Covid-19 testing revenues accordingly. Over in the US, where EKF recently received a new order for Covid-19 testing enabling an 'additional' 500,000 tests per week, I also note Thermo Fisher's update regarding Covid-19 testing revenues - Thermo Fisher Scientific Expects 12 Percent Revenue Growth in 2022 Sep 17, 2021 NEW YORK — Thermo Fisher Scientific on Friday provided initial revenue and earnings guidance for 2022, while reiterating previously disclosed financial guidance for full-year 2021. The company's 2022 figures assume 8 percent core organic revenue growth and $750 million of COVID-19 testing response revenue, as well as $6.0 billion in revenue from clinical research services provider PPD, which Thermo Fisher is set to acquire by the end of 2021. Thermo Fisher also said that each additional $100 million of COVID-19 testing response revenue over the projected $750 million would add about $.06 of additional adjusted EPS. Wall Street responded positively to the firm's 2022 guidance, pushing shares of the Waltham, Massachusetts-based company up 5 percent to $589.84 during morning trading on the New York Stock Exchange. Full story - hTTps://www.360dx.com/molecular-diagnostics/thermo-fisher-scientific-expects-12-percent-revenue-growth-2022#.YUgeqbhKiF4
wan
17/9/2021
13:41
Newtonian.
tongosti
17/9/2021
13:10
breaks wind
sirshagalot
16/9/2021
12:13
2.5 points away from cancelling the validity of most recent breakout. Will it happen? No need to guess - leave that to Mr Market. As this is a game of probabilities (not certainties which the average long term gambler is betting on) one needs to be as flexible as the wind.
tongosti
16/9/2021
08:46
Shanklin...Let's just say it's a particularly large customer (actually not sure who), but on the other hand the customer base is notably expanding.
wan
16/9/2021
08:29
wan, Thank you for your presentation notes. Re "One or two large customers extended payment terms", any idea please as to whether this is a permanent arrangement, with customers such as A*a*z*n, who perhaps have negotiated themselves particurly good terms, or a temporary situation? TIA.
shanklin
16/9/2021
08:11
Better start of the day than yesterday's action. Let's see what this baby will be up to today.
tongosti
16/9/2021
08:00
Amongst others, the following will no doubt, at the very least, assist the rapid rebound and expansion from the obsolescence of the previous STAT-site device - EKF Diagnostics to Showcase New Handheld β-ketone & Glucose Analyzer at AACC 2021 September 15, 2021 EKF Diagnostics, the global in vitro diagnostics company, announces that it will be demonstrating its new STAT-Site® WB dual analyte measurement system at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. As EKF’s first face-to-face event since COVID-19 restrictions began, this will be the premiere of the new handheld analyzer for reliable and efficient β-ketone and glucose measurement from whole blood in seconds. Visitors will be able to see firsthand how easy it is to use the CLIA waived and CE marked device in professional settings to monitor the effectiveness of diabetes control programs. EKF will also be introducing its newest hemoglobin analyzer for the US market, the Hemo Control, which provides near patient hemoglobin and hematocrit results in one test as quickly as 25 seconds. EKF’s team of point-of-care and central laboratory diagnostics experts at the Georgia World Congress Center in Atlanta, U.S., September 26-30, will also highlight the Lucica® Glycated Albumin-L. Manufactured by Asahi Kasei Pharma, it is a specific test for glycated albumin (“GA”) and is FDA cleared for sale in the U.S. where it is sold exclusively by EKF Diagnostics. This established test enables intermediate term glycemic monitoring of diabetics over the preceding 2-3 weeks. The Lucica® Glycated Albumin-L is a quantitative, enzymatic test for use on compatible clinical chemistry analyzers as a “user defined” method. The Lucica® method has appeared in numerous published studies. Glycated Albumin levels are not affected by the life span of red blood cells (“RBC”), and therefore it is a useful substitute when the HbA1c interpretation is problematic such as in the presence of hemoglobinopathies, iron deficiency, and anemias. Another key feature of glycated albumin is that it changes more rapidly and markedly than HbA1c. Therefore, GA is a good marker to monitor the effects of changes in therapy in patients with diabetes when more rapid treatment responses are needed. The STAT-Site® WB and Lucica® Glycated Albumin-L test are part of a suite of other diabetes care products that EKF will be showcasing at 2021 AACC. These include its Beta-Hydroxybutyrate LiquiColor® Assay (B-HB) and Nitro-Tab Ketone Tablets, both of which provide quick and simple tests for ketosis. Other product highlights on EKF’s stand for point-of-care and central laboratory testing include its hemoglobin analyzers, the hand-held DiaSpect Tm and the HemoPoint® H2 which offers both hemoglobin and hematocrit results in one test within 30-60 seconds. Additional analyzers on show include the Biosen RUO glucose and lactate analyzer. EKF will also discuss its growing EKF Life Sciences business which provides contract manufacturing services, as well as manufacturing diagnostic enzymes for use in medical diagnostics, pharmaceuticals and industry. This follows recent significant investment in its longstanding fermentation facility in Elkhart, Indiana, where it has been manufacturing enzymes and related biomolecules from bacterial fermentation since 1983. Full story - hTTps://infomeddnews.com/ekf-diagnostics-showcases-new-handheld-%ce%b2-ketone-glucose-analyzer/
wan
Chat Pages: 158  157  156  155  154  153  152  151  150  149  148  147  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20211028 01:47:02